Product Center
Abundant Achievements Showcasing Technological Strength
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-12-15
- Views:
(Summary description)Recently, a press conference on the evaluation results of unicorn and gazelle enterprises in Jiangsu High-Tech Zone was held in Nanjing. Ab&B Bio-Tech Co., Ltd. JS was recognized as a Potential Unicorn Enterprise in Jiangsu Province.
Abundant Achievements Showcasing Technological Strength
(Summary description)Recently, a press conference on the evaluation results of unicorn and gazelle enterprises in Jiangsu High-Tech Zone was held in Nanjing. Ab&B Bio-Tech Co., Ltd. JS was recognized as a Potential Unicorn Enterprise in Jiangsu Province.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-12-15 16:19
- Views:
Recently, a press conference on the evaluation results of unicorn and gazelle enterprises in Jiangsu High-Tech Zone was held in Nanjing. Ab&B Bio-Tech Co., Ltd. JS was recognized as a Potential Unicorn Enterprise in Jiangsu Province.
Potential Unicorn Enterprises in Jiangsu Province are innovative companies with strong innovation capabilities, rapid growth, and significant development potential. They serve as indicators of urban innovation vitality and industrial ecosystems, characterized by high growth potential, strong innovation capacity, and vast market opportunities. These enterprises are key drivers of industrial transformation in the new economy sector. This recognition as a Potential Unicorn Enterprise is a testament to the company’s innovation and development capabilities, as well as strong evidence of Zhonghui Biotechnology’s technological prowess. Recently, the company has achieved significant milestones in technological innovation. Its independently developed freeze-dried human rabies vaccine (human diploid cell-based) has made notable progress, obtaining implied clinical trial approval from the National Medical Products Administration (NMPA). This product marks the fifth candidate from the company to enter clinical trials, further expanding its product pipeline and demonstrating its technological leadership.
Relevant information
-
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially LaunchedOn May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan. - The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
- Steadily promoting national recruitment and supplementation standards, the first and only trivalent influenza virus subunit vaccine for the entire population helps global 2026 influenza prevention and control! 04-14
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
